The use of exenatide in managing markers of cardiovascular risk in patients with type 2 diabetes: A systematic review

International Journal of Environmental Research and Public Health

Volumn 13, Issue 10, 2016, Pages

  Ojo, Omorogieva ^a  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

Cardiovascular risk; Exenatide; Glycaemic control; Glycated haemoglobin; Metformin; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; INSULIN; PEPTIDE; VENOM;

CARDIOVASCULAR DISEASE; DIABETES; DISEASE TREATMENT; DRUG PRESCRIBING; HEALTH RISK; HEMOGLOBIN;

CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DATA BASE; DIASTOLIC BLOOD PRESSURE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RELEASE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN SECRETION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; HYPERGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; RISK FACTOR;

BIOMARKERS; BODY WEIGHT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PEPTIDES; RISK FACTORS; THIAZOLIDINEDIONES; VENOMS;

EID: 84989246573     PISSN: 16617827     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph13100941     Document Type: Review

References (33)

1. DeFronzo, R.A.; Ratner, R.E.; Han, J.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28, 1092-1100.
2. Saraiva, F.; Sposito, A. Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc. Diabetol. 2014, 13, 1-21.
3. Chen, Y.Y.; Lin, Y.J.; Chong, E.; Chen, P.C.; Chao, T.F.; Chen, S.A.; Chien, K.L. The impact of diabetes mellitus and corresponding hba1c levels on the future risks of cardiovascular disease and mortality: A representative cohort study in Taiwan. PLoS ONE 2015, 10, 1-12.
4. Naka, K.K.; Papathanassiou, K.; Bechlioulis, A.; Kazakos, N.; Pappas, K.; Tigas, S.; Makriyiannis, D.; Tsatsoulis, A.; Michalis, L.K. Determinants of vascular function in patients with type 2 diabetes. Cardiovasc. Diabetol. 2012, 11, 127.
5. Kendall, D.M.; Riddle, M.C.; Rosenstock, J.; Zhuang, D.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28, 1083-1091.
6. Jansson, S.P.; Svärdsudd, K.; Andersson, D.K. Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: A study of 740 patients with incident type 2 diabetes with up to 30 years’ follow-up. Diabet. Med. 2014, 31, 1055-1063.
7. National Institute for Health and Care Excellence (NICE). Type 2 Diabetes in Adults: Management; NICE Posted December 2, 2015. Available online: https://www.nice.org.uk/guidance/ng28 (accessed on 14 June 2016).
8. Nathan, D.M.; Buse, J.B.; Davidson, M.B.; Ferrannini, E.; Holman, R.R.; Sherwin, R.; Zinman, B. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009, 32, 193-203.
9. McCormack, P. Exenatide twice daily: A review of its use in the management of patients with type 2 diabetes mellitus. Drugs 2014, 74, 325-351.
10. Ferdinand, K.C.; Botros, F.T.; Atisso, C.M.; Sager, P.T. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: A pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc. Diabetol. 2016, 15, 1-12.
11. Ratner, R.E.; Maggs, D.; Nielsen, L.L.; Stonehouse, A.H.; Poon, T.; Zhang, B.; Bicsak, T.A.; Brodows, R.G.; Kim, D.D. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2006, 8, 419-428.
12. Ratner, R.; Han, J.; Nicewarner, D.; Yushmanova, I.; Hoogwerf, B.J.; Shen, L. Cardiovascular safety of exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc. Diabetol. 2011, 10, 22.
13. Anagnostis, P.; Athyros, V.G.; Adamidou, F.; Panagiotou, A.; Kita, M.; Karagiannis, A.; Mikhailidis, D.P. Glucagon-like peptide-1-based therapies and cardiovascular disease: Looking beyond glycaemic control. Diabetes Obes. Metab. 2011, 13, 302-312.
14. Saraceni, C.; Broderick, T. Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function. Drugs R&D 2007, 8, 145-153.
15. Garber, A.J. Long-acting glucagon-like peptide 1 receptor agonists: A review of their efficacy and tolerability. Diabetes Care 2011, 34 (Suppl. 2), S279-S284.
16. Bettany-Saltikov, J. How to Do a Systematic Literature Review in Nursing; Ashford Colour Press Ltd.: Gosport, Hampshire, UK, 2012.
17. Wright, R.W.; Brand, R.A.; Dunn, W.; Spindler, K.P. How to write a systematic review. Clin. Orthop. Relat. Res. 2007, 455, 23-29.
18. Scottish Intercollegiate Guidelines Network (SIGN). Critical Appraisal: Notes and Checklists. Available online: http://www.sign.ac.uk/methodology/checklists.html (accessed on 3 November 2015).
19. Gastaldelli, A.; Brodows, R.; D’Alessio, D. The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes. Clin. Endocrinol. 2014, 80, 545-553.
20. Derosa, G.; Cicero, A.; Franzetti, I.; Querci, F.; Carbone, A.; Ciccarelli, L.; D’Angelo, A.; Fogari, E.; Maffioli, P. Effects of exenatide and metformin in combination on some adipocytokine levels: A comparison with metformin monotherapy. Can. J. Phys. Pharmacol. 2013, 91, 724-732.
21. Rosenstock, J.; Shenouda, S.; Bergenstal, R.; Buse, J.; Glass, L.; Heilmann, C.; Kwan, A.; MacConell, L.; Hoogwerf, B. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012, 35, 955-958.
22. Buse, J.B.; Bergenstal, R.M.; Glass, L.C.; Heilmann, C.R.; Lewis, M.S.; Kwan, A.Y.; Hoogwerf, B.J.; Rosenstock, J. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial. Ann. Intern. Med. 2011, 154, 103-112.
23. Gill, A.; Hoogwerf, B.J.; Burger, J.; Bruce, S.; MacConell, L.; Yan, P.; Braun, D.; Giaconia, J.; Malone, J. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study. Cardiovasc. Diabetol. 2010, 9, 1-7.
24. Kadowaki, T.; Namba, M.; Imaoka, T.; Yamamura, A.; Goto, W.; Boardman, M.K.; Sowa, H. Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J. Diabetes Investig. 2011, 2, 210-217.
25. Liutkus, J.; Rosas Guzman, J.; Norwood, P.; Pop, L.; Northrup, J.; Cao, D.; Trautmann, M. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes. Metab. 2010, 12, 1058-1065.
26. Apovian, C.M.; Bergenstal, R.M.; Cuddihy, R.M.; Qu, Y.; Lenox, S.; Lewis, M.S.; Glass, L.C. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am. J. Med. 2010.
27. Simó, R.; Guerci, B.; Schernthaner, G.; Gallwitz, B.; Rosas-Guzmàn, J.; Dotta, F.; Festa, A.; Zhou, M.; Kilja ´ nski, J. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: Results from the European exenatide study. Cardiovasc. Diabetol. 2015, 14, 1-13.
28. Gallwitz, B.; Guzman, J.; Dotta, F.; Guerci, B.; Simó, R.; Basson, B.R.; Festa, A.; Kilja ´ nski, J.; Sapin, H.; Trautmann, M. et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): An open-label, randomised controlled trial. Lancet 2012, 379, 2270-2278.
29. Gallwitz, B.; Böhmer, M.; Segiet, T.; Mölle, A.; Milek, K.; Becker, B.; Helsberg, K.; Petto, H.; Peters, N.; Bachmann, O. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: A randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 2011, 34, 604-606.
30. Eskesen, K.; Jensen, M.T.; Galatius, S.; Vestergaard, H.; Hildebrandt, P.; Marott, J.L.; Jensen, J.S. Glycated haemoglobin and the risk of cardiovascular disease, diabetes and all-cause mortality in the Copenhagen City Heart Study. J. Intern. Med. 2013, 273, 94-101.
31. Elley, C.R.; Kenealy, T.; Robinson, E.; Drury, P.L. Glycated haemoglobin and cardiovascular outcomes in people with type 2 diabetes: A large prospective cohort study. Diabet. Med. 2008, 25, 1295-1301.
32. Seimon, R.V.; Espinoza, D.; Ivers, L.; Gebski, V.; Finer, N.; Legler, U.F.; Sharma, A.M.; James, W.P.; Coutinho, W.; Caterson, I.D. Changes in body weight and blood pressure: Paradoxical outcome events in overweight and obese subjects with cardiovascular disease. Int. J. Obes. 2014, 38, 1165-1171.
33. Blonde, L.; Klein, E.J.; Han, J.; Zhang, B.; Mac, S.M.; Poon, T.H.; Taylor, K.L.; Trautmann, M.E.; Kim, D.D.; Kendall, D.M. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. 2006, 8, 436-447.